Cipla Share Price Today | Stock Price & Cipla Share Screener
As of October 19, 2026, the live Cipla share price (NSE: CIPLA) is ₹1,324.10 on NSE and ₹1,331.00 on BSE, down 0.08% from the previous close, with shares trading between ₹1,321.60 and ₹1,339.00 in today's trading session, and a 52-week range of ₹1,192.40–₹1,645.10. Check CIPLA 52-week high low for the annual price range and momentum. Use the Cipla stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Cipla opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹6,612 and net income of ₹543, with EBITDA of ₹1,026, an operating margin of 14.0% and a profit margin of 8.2%.
Cipla Share Price Chart
Track the current stock price of Cipla with an interactive chart. Analyse CIPLA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Cipla stock quote in one place.
The quote of ₹1,324.10 sits between the 52-week low of ₹1,192.40 and the 52-week high of ₹1,645.10, and the latest session moved -0.08% from the previous close.
Cipla Company Profile - Fundamental Screener
Screen Cipla company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CIPLA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, with Y K Hamied listed as chairperson or CEO, and it trades under ISIN INE059A01026.
Business Overview
Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective,...more
Company Details
Classification
Identifiers and Leadership
Cipla Balance Sheet Screener
Screen CIPLA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹42,496, up from ₹37,387 in 2025.
Latest statistics put total assets at ₹42,496 and shareholder funds at ₹34,520, with a leverage ratio of 0.02.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 42,496 | 37,387 | 32,718 | 29,463 | 27,101 | 25,152 | 23,663 | 23,963 | 22,861 | 21,037 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 12,434 | 10,006 | 9,607 | 9,161 | 9,683 | 9,516 | 9,683 | 9,608 | 9,950 | 9,492 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 962 | 614 | 670 | 640 | 1,071 | 1,975 | 3,212 | 4,848 | 4,447 | 4,682 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 34,520 | 31,289 | 26,802 | 23,714 | 21,117 | 18,586 | 16,057 | 15,344 | 14,582 | 12,982 |
| Share Capital | 162 | 162 | 162 | 161 | 161 | 161 | 161 | 161 | 161 | 161 |
| Reserves & Surplus | 34,270 | 31,032 | 26,545 | 23,246 | 20,680 | 18,165 | 15,602 | 14,851 | 14,068 | 12,383 |
Cipla Income Statement Screener - Profit & Revenue Analysis
Screen Cipla income statement and profit fundamentals. Analyze CIPLA quarterly results. Cipla reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹6,612 and net profit was ₹543, equal to earnings per unit of ₹6.87, at an operating margin of 14%.
In that period expenses were ₹5,586, interest cost ₹13 and tax ₹165. The next period listed, 2026-Jun, shows revenue of ₹7,288 and net profit of ₹786.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 6,612 | 7,288 | 6,887 | 7,096 | 7,716 | 7,169 | 6,332 | 6,785 | 7,152 | 7,183 | 5,801 | 6,406 | 6,766 | 6,690 | 5,288 |
| Expenses | 5,586 | 5,927 | 5,192 | 5,179 | 5,695 | 6,095 | 4,847 | 4,978 | 5,165 | 5,084 | 4,748 | 4,835 | 4,944 | 5,051 | 4,568 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 1,026 | 1,361 | 1,695 | 1,916 | 2,022 | 1,074 | 1,484 | 1,807 | 1,986 | 2,099 | 1,053 | 1,571 | 1,821 | 1,639 | 720 |
| Operating Profit % | 14.00% | 16.00% | 21.00% | 24.00% | 24.00% | 12.00% | 20.00% | 25.00% | 26.00% | 27.00% | 16.00% | 23.00% | 25.00% | 22.00% | 13.00% |
| Depreciation | 383 | 304 | 309 | 253 | 297 | 278 | 288 | 247 | 272 | 280 | 346 | 239 | 290 | 233 | 290 |
| Interest | 13 | 17 | 14 | 14 | 13 | 14 | 18 | 18 | 15 | 15 | 34 | 16 | 26 | 30 | 18 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 707 | 1,082 | 1,504 | 1,770 | 1,854 | 893 | 1,259 | 1,611 | 1,789 | 1,916 | 745 | 1,375 | 1,594 | 1,474 | 448 |
| Tax | 165 | 296 | 290 | 478 | 500 | 219 | 327 | 436 | 484 | 342 | 224 | 377 | 439 | 405 | 77 |
| Net Profit | 543 | 786 | 1,214 | 1,292 | 1,353 | 674 | 932 | 1,176 | 1,305 | 1,575 | 522 | 998 | 1,155 | 1,068 | 371 |
| EPS | 6.87 | 9.77 | 15.13 | 16.07 | 16.73 | 8.37 | 11.63 | 14.58 | 16.13 | 19.45 | 6.51 | 12.34 | 14.01 | 13.08 | 4.49 |
Cipla Cash Flow Screener - Liquidity Fundamentals
Screen CIPLA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹3,940, and net cash flow was an inflow of ₹473.
Over the same period, investing activities used ₹2,234 and financing activities used ₹1,234.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 3,940 | 5,005 | 4,134 | 3,238 | 3,326 | 3,755 | 3,068 | 1,691 | 1,463 | 2,382 |
| Investing Activities | -2,234 | -3,682 | -2,983 | -2,376 | -1,858 | -2,374 | 114 | -1,688 | -834 | -1,304 |
Financing and Net Cash | ||||||||||
| Financing Activities | -1,234 | -1,293 | -1,200 | -958 | -1,600 | -1,240 | -2,949 | -349 | -386 | -1,326 |
| Net Cash Flow | 473 | 30 | -49 | -97 | -132 | 141 | 234 | -345 | 243 | -248 |
Cipla Shareholding Pattern Screener
See Cipla shareholding pattern with promoter, FII, and DII holdings. Check Cipla promoter holding and ownership changes for CIPLA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 29.21%, foreign institutions 22.56%, domestic institutions 31.97% and the public 13.98%, spread across 584,217 shareholders.
The shareholder count was 584,217 in 2026-Mar, compared with 578,679 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 29.21% | 29.21% | 29.20% | 29.19% | 29.21% | 29.21% | 33.47% | 30.91% |
Institutional Investors | ||||||||
| FII Holding | 22.56% | 20.21% | 26.28% | 25.25% | 24.55% | 23.93% | 25.83% | 27.81% |
| DII Holding | 31.97% | 34.63% | 28.15% | 29.26% | 30.25% | 30.72% | 24.42% | 24.95% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 13.98% | 13.74% | 14.13% | 14.10% | 13.82% | 13.84% | 14.20% | 14.24% |
| Other Holding | 2.28% | 2.20% | 2.23% | 2.20% | 2.16% | 2.29% | 2.08% | 2.09% |
| Shareholder Count | 584,217 | 578,679 | 543,420 | 549,655 | 534,587 | 540,521 | 436,154 | 463,569 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Cipla. Cipla dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹13.00 per unit for 2026-March, a yield of 0.98%, compared with ₹16.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹13.00, ₹16.00 and ₹13.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹13.00 | 0.98% |
| 2025-March | ₹16.00 | 1.31% |
| 2024-March | ₹13.00 | 0.90% |
| 2023-March | ₹8.50 | 0.57% |
| 2022-March | ₹5.00 | 0.56% |
| 2021-March | ₹5.00 | 0.49% |
| 2020-March | ₹4.00 | 0.49% |
| 2019-March | ₹3.00 | 0.71% |
| 2018-March | ₹3.00 | 0.57% |
| 2017-March | ₹2.00 | 0.37% |
Cipla Stock Index Membership - Nifty & Sensex
See which indices include Cipla stock. Check CIPLA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 45 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE 200 EQUAL WEIGHT, BSE INDEX BSE HC, BSE INDEX BSE100.
Complete Index List
Cipla Market Events Screener - Corporate Actions
Get Cipla corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Cipla stock events that may affect CIPLA share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 27, 2026, with a record date of October 27, 2026.
It is followed by Quarterly Result Announcement dated July 23, 2026 and Annual General Meeting dated June 25, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-10-27 | 2026-10-27 | Quarterly Result Announcement | NA | -5.17% |
| 2026-07-23 | 2026-07-23 | Quarterly Result Announcement | NA | -1.26% |
| 2026-06-25 | 2026-06-25 | Annual General Meeting | NA | 11.27% |
| 2026-06-05 | 2026-06-05 | Dividend | ₹ 13.00 /share | 8.23% |
| 2026-05-13 | 2026-05-13 | Quarterly Result Announcement | NA | 5.66% |
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -9.40% |
| 2025-10-30 | 2025-10-30 | Quarterly Result Announcement | NA | 3.54% |
| 2025-07-25 | 2025-07-25 | Quarterly Result Announcement | NA | -1.20% |
| 2025-07-16 | 2025-07-16 | Annual General Meeting | NA | -1.37% |
| 2025-06-27 | 2025-06-27 | Dividend | ₹ 13.00 /share | 0.08% |
| 2025-06-27 | 2025-06-27 | Dividend | ₹ 3.00 /share | 0.08% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | 6.81% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -7.57% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -9.10% |
| 2024-08-20 | 2024-08-20 | Annual General Meeting | NA | 15.95% |
Cipla Competitors Screener - Peer Stocks Comparison
Screen CIPLA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 421,995 | 34.86 | 61,674 | 12.69% | 11,565 | 37.01 |
| Divis Laboratories | 242,758 | 82.05 | 11,067 | 13.95% | 2,568 | 46.92 |
| Torrent Pharmaceuticals | 173,406 | 81.26 | 13,886 | 20.34% | 2,138 | 32.77 |
| Zydus Life Science | 112,020 | 24.78 | 27,658 | 17.64% | 5,026 | 44.73 |
| Laurus Labs | 111,310 | 100.10 | 6,868 | 22.01% | 890 | 60.45 |
| Cipla | 107,049 | 32.11 | 29,045 | 2.24% | 3,870 | 40.32 |
| Dr Reddys Laboratories | 102,916 | 32.01 | 35,059 | 3.90% | 4,158 | 57.84 |
| Aurobindo Pharma | 95,910 | 25.97 | 34,145 | 5.56% | 3,503 | 47.98 |
| Mankind Pharma | 93,988 | 47.04 | 14,636 | 14.85% | 1,938 | 37.77 |
| Lupin | 89,702 | 16.14 | 29,039 | 26.75% | 5,356 | 35.35 |
Cipla Company Announcements - News & Reports Screener
Screen CIPLA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 19, 2026.
The next most recent announcements are dated October 17, 2026 and September 28, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-19 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-09-28 | Board Meeting Intimation for The Quarter And Half Year Ended 30Th September 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-09-24 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-09-22 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-09-18 | Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-09-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-09-03 | Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company | - |
| 2026-09-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-31 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-28 | Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip Long Island NY USA | - |
| 2026-08-27 | Announcement under Regulation 30 (LODR)-Restructuring | - |
| 2026-08-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-08-26 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-08-25 | USFDA Inspection At CompanyS Manufacturing Facility In Pithampur India | - |
| 2026-08-19 | Announcement under Regulation 30 (LODR)-Scheme of Arrangement | - |
| 2026-08-11 | Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-04 | Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge Long Island New York USA | - |
| 2026-07-31 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-07-27 | Cipla Receives U.S. FDA Approval For Generic Advair Diskus® | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,324.10, within a 52-week range of ₹1,192.40 to ₹1,645.10. The P/E ratio is 32.11 and the P/B ratio is 3.13, with earnings per unit of ₹48.03. Market capitalisation stands at ₹107,049.32 Cr and the dividend yield is 0.97%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 21, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.